Navigation Links
Static killers?
Date:9/6/2013

Since its discovery in the early 1990s, the protein STAT1 (Signal Transducer and Activator of Transcription 1) has been found to be central in passing signals across immune cells, ensuring that our bodies react quickly and appropriately to threats from viruses or other pathogens. Animals without STAT1 are also prone to develop cancer, suggesting that STAT1 is somehow involved in protection against malignant cells. The STAT1 protein is known to be phosphorylated on at least two positions: phosphorylation of a particular tyrosine (tyr-701) is required for the protein to enter the cell nucleus (where it exerts its effects), while subsequent phosphorylation of a serine residue alters the way it interacts with other proteins, thereby affecting its function.

Natural Killer (NK) cells are among the first cells to respond to infections by viruses or to attack malignant cells when tumours develop. When they detect cells to be targeted, they produce a number of proteins, such as granzyme B and perforin, that enter infected cells and destroy them from within. Clearly, the lethal activity must be tightly controlled to prevent NK cells from running wild and destroying healthy cells or tissues. How is this done?

Eva Maria Putz and colleagues at the Institute of Pharmacology and Toxicology of the University of Veterinary Medicine, Vienna (Vetmeduni) have now investigated the importance of STAT1 phosphorylation in NK cells. The researchers found that when a particular serine residue (ser-727) in the STAT1 protein is mutated, NK cells produce far higher amounts of granzyme B and perforin and are far more effective at killing a wide range of tumour cells. Mice with the correspondingly mutated Stat1 gene are far less likely to develop melanoma, leukaemia or metastasizing breast cancer. On the other hand, when the same serine residue is phosphorylated, the NK cells are less able to kill infected or cancerous cells.

The Vetmeduni researchers have accumulated a body of evidence to suggest that the cyclin-dependent kinase CDK8 phosphorylates STAT1 on serine 727. Surprisingly, this phosphorylation does not require prior phosphorylation of the activating tyrosine residue, at least in NK cells. Instead, it seems to represent a way in which the lethal activity of the NK cells is kept in check. Putz is keen to note the potential significance of the finding. As she says, "If we can stop CDK8 from inactivating STAT1 in NK cells, we could stimulate tumour surveillance and thus possibly have a new handle on treating cancer, harnessing the body's own weapons against malignant cells."


'/>"/>

Contact: Susanna Kautschitsch
susanna.kautschitsch@vetmeduni.ac.at
43-125-077-1153
University of Veterinary Medicine -- Vienna
Source:Eurekalert

Related biology news :

1. Metastatic pancreatic, primary breast cancer have common growth mechanisms, study suggests
2. How cancer spreads: Metastatic tumor a hybrid of cancer cell and white blood cell
3. Modulating the immune system to combat metastatic cancer
4. LSUHSC research discovers new drug target for metastatic breast cancer
5. Thomas Jefferson University researchers discover new pathways that drive metastatic prostate cancer
6. TGen-US Oncology data guides treatment of metastatic triple-negative breast cancer patients
7. 3dMD Transitions Anatomical Research from 3D-Static to 4D-Movement Surface Imaging
8. Should high-dose interleukin-2 continue to be the treatment of choice for metastatic melanoma?
9. Cancerous tumors deliver pro-metastatic information in secreted vesicles
10. Mechanism found connecting metastatic breast cancer and arthritis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/14/2019)... ... 13, 2019 , ... Dr. Julie Reck of Veterinary Medical Center of Fort Mill ... first stem cell patient, her own geriatric Australian Shepherd, Simon, was treated in June 2019 ... to play but his body was weak, and he struggled to play fetch and other ...
(Date:8/6/2019)... , ... August 05, 2019 , ... Keck Graduate Institute ... School of Pharmacy and Health Sciences (SPHS). , “Dean Zdanowicz is highly regarded as ... Trustees Chairman Jim Widergren. “He is a great choice to build on the success ...
(Date:8/4/2019)... PRINCETON, N.J. (PRWEB) , ... August 02, 2019 ... ... expertise to assist the life science industry in advancing the development of medical ... has been recognized by PharmaVOICE magazine as one of the “100 Most Inspiring ...
Breaking Biology News(10 mins):
(Date:7/23/2019)... ... 2019 , ... While today Visikol is primarily focused on ... 3D tissue imaging , digital pathology , 3D cell culture models ... a products company. These products are focused on addressing the limitations associated with ...
(Date:7/19/2019)... ... July 18, 2019 , ... World renowned two-time Everest summiter ... with California-based charity Coalition Duchenne for its 9th Annual Expedition Mt. Kinabalu in ... funding for Duchenne muscular dystrophy and was founded by Sabahan Catherine Jayasuriya. ...
(Date:7/17/2019)... ... July 16, 2019 , ... ... agreement for the development and manufacturing of Zolgensma® (onasemnogene abeparvovec-xioi), an AveXis ... AveXis, a Novartis company, will have dedicated manufacturing space at the new, ...
(Date:7/11/2019)... ... ... At the most recent stem cell training course in Las ... R3 Heroes Program. The Veterans included individuals and families from all over the US, ... a military Veteran, teacher or first responder to receive a regenerative therapy at a ...
Breaking Biology Technology: